Etrumadenant (AB928) (C09-0880-993)

InformationEtrumadenant (AB928) Etrumadenant (AB928, A2aR/A2bR antagonist-1) is a novel dual A2aR/A2bR antagonist with Kd of 1.4 nM and 2 nM for A2aR and A2bR, respectively.TargetsA2AR (Cell-free assay); A2bR (Cell-free assay) 1.4 nM(Kd); 2 nM(Kd)In vitroConsistent with the ability of adenosine to suppress immune function, AB928 inhibits the ability of adenosine to suppress CD4 or CD8 T cell activation.In vivoEstablished AT-3-OVA tumors treated with AB928 alone has a small but significant decrease in their growth rate. Concurrent treatment with AB928 and chemotherapy results in significantly reduced tumor growth rates, when compared to chemotherapy alone.Cell Research(from reference)Cell lines：CD4+ T cells, CD8+ T cells Concentrations：1 nM, 3 nM, 10 nM, 30 nM. Specification: 0.98 Molecular Formula: C23H22N8O  Molecular Weight: 426.47 PubChem CID: 135242184 Isomeric SMILES: CC1=C(C=CC=C1C2=CC(=NC(=N2)N)C3=CN(N=N3)CC4=NC(=CC=C4)C(C)(C)O)C#N